Wolfgang Bethge
Wolfgang Bethge
Medical Center University Hospital of Tuebingen
Bestätigte E-Mail-Adresse bei med.uni-tuebingen.de
Titel
Zitiert von
Zitiert von
Jahr
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open …
J Finke, WA Bethge, C Schmoor, HD Ottinger, M Stelljes, AR Zander, ...
The lancet oncology 10 (9), 855-864, 2009
6252009
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell …
T Feuchtinger, K Opherk, WA Bethge, MS Topp, FR Schuster, ...
Blood, The Journal of the American Society of Hematology 116 (20), 4360-4367, 2010
4362010
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party …
N Kröger, E Holler, G Kobbe, M Bornhäuser, R Schwerdtfeger, ...
Blood, The Journal of the American Society of Hematology 114 (26), 5264-5270, 2009
4052009
Antilymphocyte globulin for prevention of chronic graft-versus-host disease
N Kröger, C Solano, C Wolschke, G Bandini, F Patriarca, M Pini, A Nagler, ...
New England Journal of Medicine 374 (1), 43-53, 2016
3802016
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius
G Socié, C Schmoor, WA Bethge, HD Ottinger, M Stelljes, AR Zander, ...
Blood, The Journal of the American Society of Hematology 117 (23), 6375-6382, 2011
2902011
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
ML Sorror, BM Sandmaier, BE Storer, GN Franke, GG Laport, ...
Jama 306 (17), 1874-1883, 2011
2742011
Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell …
V Icheva, S Kayser, D Wolff, S Tuve, C Kyzirakos, W Bethge, J Greil, ...
J Clin Oncol 31 (1), 39-48, 2013
2332013
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia
B Gyurkocza, R Storb, BE Storer, TR Chauncey, T Lange, JA Shizuru, ...
Journal of clinical oncology 28 (17), 2859, 2010
2182010
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
R Storb, B Gyurkocza, BE Storer, ML Sorror, K Blume, D Niederwieser, ...
Journal of Clinical Oncology 31 (12), 1530, 2013
2122013
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
H Pfeifer, B Wassmann, W Bethge, J Dengler, M Bornhäuser, M Stadler, ...
Leukemia 27 (6), 1254-1262, 2013
1992013
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
C Kahl, BE Storer, BM Sandmaier, M Mielcarek, MB Maris, KG Blume, ...
Blood, The Journal of the American Society of Hematology 110 (7), 2744-2748, 2007
1732007
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
GG Laport, BM Sandmaier, BE Storer, BL Scott, MJ Stuart, T Lange, ...
Biology of Blood and Marrow Transplantation 14 (2), 246-255, 2008
1582008
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update
WA Bethge, C Faul, M Bornhäuser, G Stuhler, DW Beelen, P Lang, ...
Blood Cells, Molecules, and Diseases 40 (1), 13-19, 2008
1582008
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
WA Bethge, U Hegenbart, MJ Stuart, BE Storer, MB Maris, MED Flowers, ...
Blood 103 (3), 790-795, 2004
1492004
Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study …
N Kroger, S Iacobelli, G Franke, U Platzbecker, R Uddin, K Hubel, ...
1462017
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ...
Nature medicine 24 (3), 282-291, 2018
1402018
Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors
R Handgretinger, A Geiselhart, A Moris, R Grau, O Teuffel, W Bethge, ...
New England Journal of Medicine 340 (4), 278-284, 1999
1381999
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study
B Federmann, M Bornhauser, C Meisner, L Kordelas, DW Beelen, ...
haematologica 97 (10), 1523, 2012
1272012
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
H Alchalby, A Badbaran, T Zabelina, G Kobbe, J Hahn, D Wolff, ...
Blood, The Journal of the American Society of Hematology 116 (18), 3572-3581, 2010
1242010
Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device
M Schumm, P Lang, W Bethge, C Faul, T Feuchtinger, M Pfeiffer, W Vogel, ...
Cytotherapy 15 (10), 1253-1258, 2013
1202013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20